Towards a specific immunosuppression for pancreas and islet grafts.
This brief article is a summary of the presentations at a meeting organized in Lyon, France, to discuss strategies of reducing post-transplant diabetes mellitus and to suggest an ideal immunosuppressive therapy for pancreatic and islet allografts.
Jindal
R M
RM
Department of Surgery, University of Glasgow, UK. jindalr@aol.com
Dubernard
J M
JM
D003920:Diabetes Mellitus / Q000209:etiology / Q000517:prevention & control; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016381:Islets of Langerhans Transplantation / Q000009:adverse effects / Q000276:immunology; D016035:Pancreas Transplantation / Q000009:adverse effects / Q000276:immunology; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D016559:Tacrolimus